课题基金 / 基金详情

Novel Anti-Malarials by Combinatorial Pharmacogenomics

Novel Anti-Malarials by Combinatorial Pharmacogenomics
组合药物基因组学的新型抗疟药
批准号:
6665332
负责人:
JOSEPH L. DERISI
金额:
$83.54万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-09-30 至 2007-07-31

项目摘要

项目成果

JOSEPH L. DERISI的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The goal of the proposed work is the development of novel quinoline-based anti-malarial compounds. The work will be accomplished by the cooperation of of two academic labs, Kip Guy and Joseph DeRisi, and two industrial partners, GenoSpectra, Inc., and Stanford Research Institute (SRI), Inc. Quinolines have a long and rich history of anti-malarial use, yet the diversity of tested compounds to date has been limited by a narrow range of synthetic techniques. Little is known about the effects these drugs have on parasites at the molecular level. Additional information at the whole genome level could thus greatly accelerate both the understanding of these compounds and the optimization of their structure for the purpose of subverting the parasite. The Guy Lab will implement a combinatorial synthesis program aimed at generating a library encoding approximately 80% novel quinolines and test them for activity against Plasmodium falciparum in a high throughput in vitro assay system. In parallel, the Guy Lab will produce and make publicly available a structure activity database for known and tested quinoline structures. The DeRisi lab will commence expression profiling of all the known and available anti-malarial therapeutics using a near-whole genome array and a novel bioreactor growth system. Expression data for known anti-malarial drugs will be used in combination with expression data gathered for top candidate compounds emerging from the Guy Lab synthesis effort to create a structure-activity expression relationship. Top candidates will also be transferred to SRI, Inc., for rigorous toxicology testing. RNA material from cultured hepatocytes treated with candidate compounds will be used to gather expression responses using whole human genome chips developed by GenoSpectra, Inc. The compiled relationships from known anti-malarials, novel quinolines, and toxicology will then be used to guide and optimize additional synthesis efforts toward the ultimate goal of producing effective therapeutics.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Autoimmune Encephalitis - Ataxia and Psychiatric Disease: Identifying and Characterizing Novel Antibody Targets
Autoimmune Encephalitis - Ataxia and Psychiatric Disease: Identifying and Characterizing Novel Antibody Targets
Detection and discovery of viral pathogens associated with dengue-like symptoms
  • 批准号:
    8260246
  • 项目类别:
  • 资助金额:
    $14.0万
  • 财政年份:
    2011
  • 负责人:
    JOSEPH L. DERISI
  • 依托单位:
High Throughput Functional Genomics and Proteomics
海外基金